Section Arrow
FULC.NASDAQ
- Fulcrum Therapeutics
Quotes are at least 15-min delayed:2024/09/20 18:34 EDT
Last
 3.35
-0.1 (-2.90%)
Day High 
3.4393 
Prev. Close
3.45 
1-M High
9.9 
Volume 
1.96M 
Bid
3.3
Ask
3.39
Day Low
3.31 
Open
3.41 
1-M Low
2.865 
Market Cap 
215.28M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 5.46 
20-SMA 7.12 
50-SMA 8.12 
52-W High 13.7 
52-W Low 2.865 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.34/-1.06
Enterprise Value
223.91M
Balance Sheet
Book Value Per Share
4.39
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
2.81M
Operating Revenue Per Share
0.04
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CEROCERo Therapeutics Holdings0.115+0.028+32.18%-- 
NBYNovaBay Pharmaceuticals0.74+0.2431+48.92%-- 
ADMAADMA Biologics19.98+0.24+1.22%141PE
ROIVRoivant Sciences Ltd11.97+0.05+0.42%2.08PE
TGTXTG Therapeutics24.65-0.63-2.49%37.18PE
Quotes are at least 15-min delayed:2024/09/20 18:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.